4 assets in Oropharynx Cancer

Therapeutic assets addressing Oropharynx Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Oropharynx Cancer	Turnstone Biologics, Corp.	P2	BB (64)
e7 tcr-t cells Oropharynx Cancer	Christian Hinrichs	P2	B (60)
Cis-Diamminedichloroplatinum Ii Oropharynx Cancer	Loren Mell, MD	P2	CCC (53)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Oropharynx Cancer	VM Oncology, LLC	P1/2	CCC (48)